PsyHistio: Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis
Study Details
Study Description
Brief Summary
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of anxiety symptoms and an addictive profile. However, no study to date has precisely investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH patients.
This study should allow:
-
to assess the prevalence of psychiatric disorders co-morbid in PLCH patients
-
a targeted and more effective management of patients
-
a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Pulmonary Langerhans cell histiocytosis (PLCH) Adults with pulmonary Langerhans cell histiocytosis |
Other: Evaluation of co-morbid psychiatric disorders
Added scales :
Mini Internationnal Neuropsychiatric Interview
Fagerström test
DSM-5 Scale
Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics
Expired carbon monoxide for patients using nicotine substitutes
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test [at inclusion]
The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder
Secondary Outcome Measures
- Proportion of patients with at least one comorbid addictive disorder among: tobacco, alcohol, cannabis, benzodiazepines, cocaine, opiates [at inclusion]
Definition and diagnosis of addictive disorder will be assessed with Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
- Proportion of patients with active tobacco consumption with or without comorbid psychiatric disorder [at inclusion]
Tobacco consumption will be assessed by Fagerström survey and DSM-5, cotinine in urine quantification and expired carbon monoxide for patients using nicotine substitutes. Fargerstrom test evaluates the dependence on cigarettes from 0 to 10 (0 indicated a very low dependence and 10 a very strong dependence)
- Proportion of patients with persistent tobacco consumption despite nicotine replacement treatment [at inclusion]
Tobacco consumption will be assessed by Fagerström survey and DSM-5 and expired carbon monoxide for patients with nicotine substitutes
- Number of previous tobacco weaning episodes and co-morbid psychiatric disorders [at inclusion]
- Number of co-morbid psychiatric disorders [at inclusion]
- Factors associated with psychiatric disorders as assessed by Mini International Neuropsychiatric Interview (MINI) test [at inclusion]
The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients of 18 years of age or older with PLCH diagnosed at adulthood
-
Patients affiliated to the French Health Care System
-
Informed patients
Exclusion Criteria:
-
Patient unable to understand the interview (language barrier)
-
Patient under guardianship or curatorship
-
Patient under AME (French medical help for foreigners)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Saint-Louis, Centre de référence national des histiocytoses, Service de Pneumologie | Paris | France |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP210292